Concourse Financial Group Securities, Inc. Context Therapeutics Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q1 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q1 2025 May 14, 2025	BUY	$0.61 - $1.25 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$0.98 - $2.35 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.79 - $2.66 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.24 - $2.19 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.92 - $1.38 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.79 - $1.41 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.9 - $1.59 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.9 - $1.59 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.48 - $1.6 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.56 - $1.06 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.61 - $1.42 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.11 - $2.08 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.29 - $2.66 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.72 - $2.82 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.66 - $7.45 $0 - $0

Others Institutions Holding CNTX

# of Institutions

Shares Held

79M

Call Options Held

Put Options Held

View Full List

About Context Therapeutics Inc.

Ticker CNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,966,100
Market Cap $10.9M
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...

More about CNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account